The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Value Of The Rare Biomarkers Specimen Collection And Stabilization Market Projected To Expand During 2026–2030?
The market size for rare biomarkers specimen collection and stabilization has seen considerable expansion in recent years. This market is projected to increase from $35.29 billion in 2025 to $38.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.3%. The growth observed in previous periods is attributable to factors such as the rise in molecular diagnostics research, the broadening of oncology biomarker studies, the widespread availability of plasma-based testing methods, heightened clinical trial activity, and the increasing adoption of biobanking practices.
The rare biomarkers specimen collection and stabilization market is projected to experience substantial expansion over the upcoming years. This market is forecast to reach a valuation of $55.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This anticipated growth is driven by several factors including the rising embrace of precision diagnostics, a heightened need for early disease identification, the broadening scope of genomic and transcriptomic testing, increased financial commitments to biomarker-guided drug discovery, and the expanding incorporation of AI in biomarker assessment. Key developments expected during this period involve a greater uptake of liquid biopsy collection methods, the expanded utilization of sophisticated stabilization reagents, an escalating requirement for preserving high-sensitivity biomarkers, the widening application of non-invasive diagnostics, and a sharpened emphasis on the integrity and traceability of samples.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
Which Core Factors Are Supporting The Expansion Of The Rare Biomarkers Specimen Collection And Stabilization Market?
The rising incidence of cancer is anticipated to drive the expansion of the rare biomarker specimen collection and stabilization market moving forward. Cancer encompasses a diverse group of diseases characterized by the uncontrolled division and spread of abnormal cells throughout the body. The escalation in cancer cases is attributed to elements such as environmental exposures, lifestyle choices including smoking and poor dietary habits, and genetic vulnerabilities, all of which heighten the demand for precise diagnostic and monitoring tools. In oncology, rare biomarker specimen collection and stabilization are vital for ensuring the accurate preservation of blood- and tissue-based biomarkers, which are critical for early detection, molecular profiling, and guiding therapy selection. As an illustration, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, forecasted over 35 million new cancer cases by 2050, marking a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer is a key factor propelling the growth of the rare biomarker specimen collection and stabilization market.
What Segment Categories Are Evaluated In The Rare Biomarkers Specimen Collection And Stabilization Market Study?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum
What Trends Are Affecting The Growth Of The Rare Biomarkers Specimen Collection And Stabilization Market?
Major companies operating in the rapid diagnostics market are prioritizing advancements and innovation, such as rapid diagnostic testing tools, to enhance diagnostic accuracy, reduce turnaround times, and improve patient outcomes in point-of-care settings. Rapid diagnostic testing tools are medical devices designed to quickly detect the presence of specific diseases or conditions, typically providing results within minutes at the point of care. For instance, in May 2025, SEKISUI Diagnostics, a US-based medical diagnostics manufacturer, launched the OSOM RSV Test, a rapid diagnostic tool for detecting respiratory syncytial virus (RSV). This test is intended for use in professional healthcare settings and delivers results in just 15 minutes. It employs a rapid immunochromatographic assay to qualitatively detect RSV nucleoprotein antigen. The test uses anterior nasal swab specimens collected from patients showing symptoms of respiratory infection, and its quick turnaround time supports timely and effective clinical decision-making.
Who Are The Companies Shaping The Rare Biomarkers Specimen Collection And Stabilization Market Landscape?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
Access The Complete Rare Biomarkers Specimen Collection And Stabilization Market Report:
Which Area Represents The Largest Portion Of The Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Rare Biomarkers Specimen Collection And Stabilization Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp
Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company
Blood Transfusion Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report
Hematology Diagnostic Devices And Equipment Global Market Report 2026
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model